Showing results (201-210 of 255) with videos related to

Sort By:
Pageof 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trialJ Rodon, J C Soria, R Berger, et al.
Respiratory Medicine and Research|June 22, 2020
Proposals for managing patients with thoracic malignancies during COVID-19 pandemicN Girard, L Greillier, G Zalcman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancerG V Scagliotti, I Bondarenko, F Blackhall, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2020
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer expertsM Früh, C M Panje, M Reck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2022
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket studyV Subbiah, R J Kreitman, Z A Wainberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 2, 2022
Impact of acetaminophen on the efficacy of immunotherapy in cancer patientsA Bessede, A Marabelle, J P Guégan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsJ-C Soria, F DeBraud, R Bahleda, et al.
Scientific Reports|May 18, 2022
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platformM Morfouace, S Novello, A Stevovic, et al.
European Journal of Cancer (Oxford, England : 1990)|July 31, 2012
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancerM Arnedos, V Scott, B Job, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2012
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclassesW E Pierceall, K A Olaussen, V Rousseau, et al.
Pageof 26